Frontline PARP inhibitor maintenance therapy provides a substantial PFS benefit for newly diagnosed epithelial ovarian cancer patients with BRCA pathogenic variants, with the most pronounced efficacy observed in mutations located within the DNA-binding domains of BRCA1 and BRCA2. The gene discussed is BRCA2; the disease is ovarian carcinoma.